Frank Reynolds, of InVivo Therapeutics (NVIV), says the company is on the verge of unprecedented technology for the treatment of the spinal cord.
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Aduro BioTech, a OneMedForum presenting company is engineering Listeria to treat Pancreatic Cancer and other infectious diseases.
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
Though selected in order to give a platform to lesser recognized businesses, the companies presenting demonstrated the vast diversity of the healthcare and life science spaces.
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.
Below are some updates and developments from the past week.